<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">Immunomodulant therapies currently used in NMD patients may help against SARS-CoV-2 infection. Some severe SARS-CoV-2 cases with acute respiratory insufficiency may be associated with complex immune dysregulation and excessive activation of inflammatory pathways [
 <xref ref-type="bibr" rid="CR41">41</xref>]. At the time of writing, some cytokine inhibition strategies are currently being tested for the treatment of COVID-19, such as Tocilizumab and Eculizumab, but their efficacy in COVID-19 patients is still unclear; several clinical trials (NCT04288713 for eculizumab; NCT04317092; NCT04310228 and others for tocilizumab) are currently ongoing worldwide.
</p>
